Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

1,501.76

1,409.01

1,504.78

1,516.23

1,490.70

1,310.47

1,340.08

Other Operating Income

0.00

Total Operating income

1,501.76

1,409.01

1,504.78

1,516.23

1,490.70

1,310.47

1,340.08

Raw Material Cost

988.85

976.28

1,047.76

1,025.60

1,109.06

897.19

970.38

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

14.73

17.89

16.56

18.91

24.00

33.13

33.72

Selling and Distribution Expenses

247.20

340.22

210.18

180.00

180.07

265.47

205.02

Other Expenses

2.64

3.52

6.12

4.67

1.67

5.33

1.72

Total Expenditure (Excl Depreciation)

1,277.17

1,369.54

1,335.67

1,271.19

1,329.83

1,249.06

1,226.29

Operating Profit (PBDIT) excl Other Income

224.60000000000002

39.5

169.1

245

160.9

61.4

113.80000000000001

Other Income

-101.75

-90.87

-28.58

181.96

91.45

-189.77

54.91

Operating Profit (PBDIT)

111.40

-44.82

237.28

467.78

345.20

-242.91

271.27

Interest

14.73

17.89

16.56

18.91

24.00

33.13

33.72

Exceptional Items

128.86

-71.03

17.61

18.16

-48.44

248.17

-3.26

Gross Profit (PBDT)

512.91

432.73

457.02

490.63

381.64

413.29

369.70

Depreciation

0.00

107.93

107.52

100.70

99.78

90.24

90.80

Profit Before Tax

225.53

-241.68

130.81

366.33

172.98

-118.11

143.48

Tax

22.92

-32.22

28.97

43.58

23.60

-7.39

3.62

Provisions and contingencies

0.00

Profit After Tax

211.66

-223.87

143.94

286.21

167.42

-144.23

126.69

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

211.66

-223.87

143.94

286.21

167.42

-144.23

126.69

Share in Profit of Associates

0.00

Minority Interest

-0.23

-6.47

-0.31

-0.27

-0.45

-22.46

-0.22

Other related items

0.00

Consolidated Net Profit

211.44

-230.34

143.63

285.94

166.97

-166.69

126.47

Equity Capital

0.00

Face Value

1.13

1.11

1.09

1.1

1.07

1.06

1.11

Reserves

13,822.95

13,400.23

13,519.90

13,320.74

13,182.65

12,928.76

13,440.58

Earnings per share (EPS)

0.14

-0.15

0.1

0.2

0.11

-0.1

0.09

Diluted Earnings per share

0.14

-0.15

0.1

0.2

0.11

-0.1

0.09

Operating Profit Margin (Excl OI)

14.19%

-4.39%

10.52%

12.21%

10.33%

-10.94%

9.37%

Gross Profit Margin

15.02%

-9.49%

15.84%

30.8%

18.3%

-2.13%

17.48%

PAT Margin

14.09%

-15.89%

9.57%

18.88%

11.23%

-11.01%

9.45%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is 6.59% vs -6.37% in Dec 2025

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is 191.79% vs -260.38% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 363.48% vs -82.70% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is -17.88% vs 7.83% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(HKD)

Change(%)

Net Sales

1,501.76

Other Operating Income

0.00

Total Operating income

1,501.76

Raw Material Cost

988.85

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

14.73

Selling and Distribution Expenses

247.20

Other Expenses

2.64

0.00

2.64

Total Expenditure (Excl Depreciation)

1,277.17

Operating Profit (PBDIT) excl Other Income

224.59

0.00

224.59

Other Income

-101.75

Operating Profit (PBDIT)

111.40

Interest

14.73

Exceptional Items

128.86

Gross Profit (PBDT)

512.91

Depreciation

0.00

Profit Before Tax

225.53

Tax

22.92

Provisions and contingencies

0.00

Profit After Tax

211.66

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

211.66

Share in Profit of Associates

0.00

Minority Interest

-0.23

Other related items

0.00

Consolidated Net Profit

211.44

Equity Capital

0.00

Face Value

1.13

0.00

Reserves

13,822.95

Earnings per share (EPS)

0.14

Diluted Earnings per share

0.14

Operating Profit Margin (Excl OI)

14.19%

0.00

14.19%

Gross Profit Margin

15.02%

0.00

15.02%

PAT Margin

14.09%

0.00

14.09%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 150.18 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 6.59% vs -6.37% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 0.74% vs -0.22% in Mar 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit 21.14 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 191.79% vs -260.38% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 26.59% vs -0.71% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 21.32 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 363.48% vs -82.70% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -15.96% vs -38.23% in Mar 2025

Quarterly - Interest

Interest 1.47 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -17.88% vs 7.83% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -38.75% vs -51.12% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 14.19%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025